[go: up one dir, main page]

CA2573842A1 - Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2 - Google Patents

Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2 Download PDF

Info

Publication number
CA2573842A1
CA2573842A1 CA002573842A CA2573842A CA2573842A1 CA 2573842 A1 CA2573842 A1 CA 2573842A1 CA 002573842 A CA002573842 A CA 002573842A CA 2573842 A CA2573842 A CA 2573842A CA 2573842 A1 CA2573842 A1 CA 2573842A1
Authority
CA
Canada
Prior art keywords
composition
glycan
immunoglobulin
antibody
glycans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002573842A
Other languages
English (en)
Inventor
Tillman U. Gerngross
Huijuan Li
Stefan Wildt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycofi Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2573842A1 publication Critical patent/CA2573842A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002573842A 2004-07-21 2005-07-19 Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2 Abandoned CA2573842A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US59003004P 2004-07-21 2004-07-21
US59005204P 2004-07-21 2004-07-21
US60/590,030 2004-07-21
US60/590,052 2004-07-21
PCT/US2005/025656 WO2006014683A2 (fr) 2004-07-21 2005-07-19 Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2

Publications (1)

Publication Number Publication Date
CA2573842A1 true CA2573842A1 (fr) 2006-02-09

Family

ID=35502713

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002573842A Abandoned CA2573842A1 (fr) 2004-07-21 2005-07-19 Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2

Country Status (5)

Country Link
EP (1) EP1771477A2 (fr)
JP (1) JP2008515772A (fr)
AU (1) AU2005269763A1 (fr)
CA (1) CA2573842A1 (fr)
WO (1) WO2006014683A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
KR100787073B1 (ko) 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
WO2008008482A2 (fr) * 2006-07-13 2008-01-17 Genentech, Inc. Polypeptides de liaison à br3 modifiés
JP5298021B2 (ja) 2006-10-12 2013-09-25 ジェネンテック， インコーポレイテッド リンホトキシン−αに対する抗体
JP2012503471A (ja) * 2008-05-30 2012-02-09 グライコフィ， インコーポレイテッド 末端アルファ−１，３−結合ガラクトースを有するタンパク質の製造のための酵母株
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
US8458171B2 (en) 2009-01-30 2013-06-04 Google Inc. Identifying query aspects
WO2010099153A2 (fr) * 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Ingénierie métabolique d'une voie d'assimilation du galactose dans la levure glycosynthétisée pichia pastoris
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
BR112014003110A2 (pt) * 2011-08-10 2018-10-09 Lab Francais Du Fractionnement composição, método para produção de uma população altamente galactosilada de anticorpos, células epiteliais de glândula mamária e mamífero não humano tramsgênico
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
WO2013158279A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2956003A2 (fr) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Protéines à glycosylation modifiée et leurs procédés de production
BR112015019341A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
CA2905010A1 (fr) 2013-03-12 2014-09-18 Abbvie Inc. Anticorps humains qui se lient au tnf-alpha et leurs procedes de preparation
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101001243B1 (ko) * 2001-12-27 2010-12-17 글리코파이, 인크. 포유동물-유형 탄수화물 구조의 설계 방법

Also Published As

Publication number Publication date
AU2005269763A1 (en) 2006-02-09
EP1771477A2 (fr) 2007-04-11
WO2006014683A2 (fr) 2006-02-09
WO2006014683A3 (fr) 2006-06-08
JP2008515772A (ja) 2008-05-15

Similar Documents

Publication Publication Date Title
US20090162377A1 (en) Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
US20100184143A1 (en) Immunoglobulins comprising predominantly a Man3GlcNAc2 glycoform
US20060029604A1 (en) Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
CA2573745A1 (fr) Immunoglobulines contenant principalement un glycoforme de type glcnac2man3glcnac2
US20060257399A1 (en) Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
US20060034830A1 (en) Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060034828A1 (en) Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060024304A1 (en) Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
CA2573842A1 (fr) Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2
WO2006071856A2 (fr) Immunoglobulines comprenant principalement une glycoforme man5glcnac2
US20090226464A1 (en) Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
AU2005269765A1 (en) Immunoglobulins comprising predominantly a Man3GlcNAc2 glycoform
CA2590441A1 (fr) Immunoglobulines comprenant principalement un glycoforme galglcnacman5glcnac2
CA2573864A1 (fr) Immunoglobulines comprenant principalement une glycoforme glcnacman<sb>5</sb>glcnac<sb>2</sb>
CA2573554A1 (fr) Immunoglobulines comprenant principalement une glycoforme man<sb>5</sb>glcnac<sb>2</sb>
CN101001875A (zh) 主要包含man5glcnac2糖形的免疫球蛋白
CN1989154A (zh) 包含占优势的gal2glcnac2man3glcnac2糖形的免疫球蛋白
CN101257922A (zh) 主要包含Man7GlcNAc2、Man8GlcNAc2糖形式的免疫球蛋白
CN101001876A (zh) 包含占优势的GlcNacMAN5GLCNAC2糖形的免疫球蛋白

Legal Events

Date Code Title Description
FZDE Dead